ZA964445B - Oligonucleotides specific for hepatitis b virus - Google Patents

Oligonucleotides specific for hepatitis b virus

Info

Publication number
ZA964445B
ZA964445B ZA964445A ZA964445A ZA964445B ZA 964445 B ZA964445 B ZA 964445B ZA 964445 A ZA964445 A ZA 964445A ZA 964445 A ZA964445 A ZA 964445A ZA 964445 B ZA964445 B ZA 964445B
Authority
ZA
South Africa
Prior art keywords
hepatitis
virus
oligonucleotides specific
hbv
kits
Prior art date
Application number
ZA964445A
Other languages
English (en)
Inventor
Charles J Craig
Bruce L Frank
John Goodchild
Raymond Jupp
Robert E Kilkuskie
John S Mills
Noel A Roberts
Peter C Roberts
Andrew Slade
Original Assignee
Hoffmann La Roche
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Hybridon Inc filed Critical Hoffmann La Roche
Publication of ZA964445B publication Critical patent/ZA964445B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA964445A 1995-06-06 1996-05-30 Oligonucleotides specific for hepatitis b virus ZA964445B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46739795A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
ZA964445B true ZA964445B (en) 1996-12-06

Family

ID=23855522

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964445A ZA964445B (en) 1995-06-06 1996-05-30 Oligonucleotides specific for hepatitis b virus

Country Status (10)

Country Link
US (2) US5856459A (xx)
EP (1) EP0832211B1 (xx)
AT (1) ATE233318T1 (xx)
AU (1) AU6125296A (xx)
CA (1) CA2226458A1 (xx)
DE (1) DE69626393T2 (xx)
DK (1) DK0832211T3 (xx)
ES (1) ES2188760T3 (xx)
WO (1) WO1996039502A1 (xx)
ZA (1) ZA964445B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
CA2270401A1 (en) 1996-10-31 1998-05-07 Biogen, Inc. Novel hepatitis b virus inhibitors
CN1057302C (zh) * 1997-08-27 2000-10-11 中国科学院上海生物化学研究所 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸
CN1215058A (zh) * 1997-10-21 1999-04-28 中国科学院上海生物化学研究所 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用
CA2352738A1 (en) 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
WO2001064959A1 (en) * 2000-03-02 2001-09-07 Akzo Nobel N.V. Detection of hepatitis b virus rna
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
CN101113160A (zh) * 2001-05-16 2008-01-30 米珍尼克斯公司 基于核酸的化合物及其使用方法
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
WO2003106714A1 (en) * 2002-06-14 2003-12-24 Gen-Probe Incorporated Compositions and methods for detecting hepatitis b virus
EP1403385A1 (en) * 2002-09-27 2004-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for assaying replication of HBV and testing susceptibility to drugs
EA008777B1 (ru) * 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
CN102762215A (zh) 2009-10-16 2012-10-31 葛兰素集团有限公司 Hbv反义抑制剂
PT3505528T (pt) * 2011-04-21 2021-02-23 Glaxo Group Ltd Modulação da expressão do vírus da hepatite b (vhb)
JP6165723B2 (ja) 2011-06-30 2017-07-19 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression
WO2019240503A1 (ko) * 2018-06-12 2019-12-19 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
AU662304B2 (en) * 1990-10-22 1995-08-31 Fox Chase Cancer Center DNA construct for providing RNA therapy
EP0666923A1 (en) * 1991-09-05 1995-08-16 The University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
JPH09507062A (ja) * 1993-12-23 1997-07-15 アポロン インク． 抗ｂ型肝炎ウイルスオリゴヌクレオチド
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication

Also Published As

Publication number Publication date
WO1996039502A1 (en) 1996-12-12
EP0832211A1 (en) 1998-04-01
DE69626393T2 (de) 2003-12-04
US5856459A (en) 1999-01-05
US6984729B1 (en) 2006-01-10
DE69626393D1 (de) 2003-04-03
EP0832211B1 (en) 2003-02-26
AU6125296A (en) 1996-12-24
CA2226458A1 (en) 1996-12-12
ATE233318T1 (de) 2003-03-15
ES2188760T3 (es) 2003-07-01
DK0832211T3 (da) 2003-05-26

Similar Documents

Publication Publication Date Title
ZA964445B (en) Oligonucleotides specific for hepatitis b virus
DE69829115D1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
ATE211393T1 (de) Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
NO983716L (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
EP1115286A4 (en) METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM
DE69330372T2 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
DK0821690T3 (da) Nukleotidanaloger til behandling af virusinfektioner
CA2210353A1 (en) Stabilized external guide sequences
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
DE60001770D1 (de) Verfahren zur Herstellung von eigenleitfähigen Copolymeren und damit hergestellte eigenleitfähige Copolymer-Verbindungen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
WO2001045712A8 (de) Arzneimittelkombinationen gegen virale erkrankungen
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
HUP9900680A3 (en) Acyclic nucleoside derivatives, process for producing them, pharmaceutical compositions containing them and method for the treatment of viral infections
ES2091928T3 (es) Metodos de prevencion de la replicacion virica.
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
EP1331267A3 (en) Oligonucleotides specific for hepatitis C virus
WO1996039501A3 (en) Oligonucleotides specific for human papillomavirus
DE69300901D1 (de) Verfahren zur Reinigung von 1,1,1,2-Tetrafluorethan.
FR2679235B1 (fr) Methode de purification des aminoacides, des acides nucleiques et de leurs derives.
DE60335564D1 (de) Antiinfektiöse mittel
FR2691161B1 (fr) Enzyme de lévane saccharase, procédé pour sa préparation, micro-organismes qui le produisent et compositions le contenant.
EP1288296A3 (en) Method and reagent for inhibiting HBV viral replication